Drug
Zasocitinib clinical trials
Also written TAK-279 and NDI-034858.
- studies test it
- 26
- open now
- 10
- in phase 3
- 11
- first study started
- 2021
Keep track of what changes. Save the zasocitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- TAK-279
- 22
Studies by the year they started
25 studies that test it; most in 2024 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 8
- Phase 3
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses zasocitinib is read from its arms, and is right about nine times in ten.
Testing it · 26
- A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisNot yet recruitingPhase 3TakedaNCT07752108Written as Zasocitinib
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesRecruitingPhase 3TakedaNCT06671483Written as Zasocitinib
- A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)Not yet recruitingPhase 3TakedaNCT07871721Written as Zasocitinib
- A Study of Zasocitinib in Adults With Nonsegmental VitiligoRecruitingPhase 2TakedaNCT07108283Written as Zasocitinib
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 2TakedaNCT06233461Written as TAK-279
- A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisRecruitingPhase 3TakedaNCT07250802Written as Zasocitinib
- Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisRecruitingPhase 3TakedaNCT07286058Written as Zasocitinib
- A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's DiseaseRecruitingPhase 2TakedaNCT07403968Written as Zasocitinib
- A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)RecruitingPhase 2TakedaNCT06764615Written as Zasocitinib
- A Study of Zasocitinib in Adults With Hidradenitis SuppurativaRecruitingPhase 2TakedaNCT07244263Written as Zasocitinib (Dose A)
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesActive, not recruitingPhase 3TakedaNCT06671496Written as Zasocitinib
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 2TakedaNCT06254950Written as TAK-279
- A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedPhase 3TakedaNCT06323356Written as TAK-279
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisActive, not recruitingPhase 3TakedaNCT06550076Written as TAK-279
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisCompletedPhase 3TakedaNCT06973291Written as Zasocitinib
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodCompletedPhase 3TakedaNCT06108544Written as TAK-279
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentCompletedPhase 3TakedaNCT06088043Written as TAK-279
- A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy AdultsCompletedPhase 1TakedaNCT06793943Written as Zasocitinib
- A Study of TAK-279 in Adults With or Without Liver DamageCompletedPhase 1TakedaNCT05976321Written as TAK-279
- A Study of TAK-279 in Healthy Chinese AdultsCompletedPhase 1TakedaNCT06111547Written as TAK-279
Codes
What other systems call zasocitinib · ClinicalTrials.gg INT016156
- UNII (FDA) C293MNS6TQZASOCITINIBOne source FDA
- NCI Thesaurus C199133ZasocitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C293MNS6TQ | ZASOCITINIB | One source FDA |
| NCI Thesaurus | C199133 | Zasocitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.